{"doi":"10.1128/spectrum.04081-22","title":"Determining the Time of Booster Dose Based on the Half-Life and Neutralization Titers against SARS-CoV-2 Variants of Concern in Fully Vaccinated Individuals","abstract":"Despite improved understanding of the biology of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the evolutionary trajectory of the virus is uncertain, and the concern of future antigenically distinct variants remains. Current recommendations for a COVID-19 vaccine booster dose are primarily based on neutralization capacity, effectiveness against circulating variants of concern (VOC), and other host factors. We hypothesized that measuring neutralizing antibody titers against SARS-CoV-2 VOC together with half-life information can be used to dictate the time of booster vaccination. Through detailed analysis of neutralizing antibodies against VOC among COVID-19-naive vaccinees receiving either of two mRNA vaccines, we found that the time it took for 50% neutralization titers to decline to a reference level of protection was longer in the Moderna than in the Pfizer group, which supports our hypothesis. In response to future VOC with potentially high morbidity and mortality, our proof-of-concept study provides a framework to determine the optimal time of a booster dose at the individual level.","journal":"Microbiology Spectrum","year":2023,"id":375108,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9557,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":968800,"name":"Yen-Chia Lin","orcid":null,"position":1,"is_corresponding":false},{"id":743813,"name":"Lauren L. Ching","orcid":"0000-0003-3146-2745","position":2,"is_corresponding":false},{"id":780195,"name":"Jih‐Jin Tsai","orcid":"0000-0003-2226-8916","position":3,"is_corresponding":false},{"id":894053,"name":"Kyle Ishikawa","orcid":"0000-0002-4181-8648","position":4,"is_corresponding":false},{"id":743812,"name":"Wen-Yang Tsai","orcid":"0000-0002-3407-8223","position":5,"is_corresponding":false},{"id":782615,"name":"John J. Chen","orcid":"0000-0003-0170-0407","position":6,"is_corresponding":false},{"id":522329,"name":"Vivek R. Nerurkar","orcid":"0000-0002-2044-2784","position":7,"is_corresponding":false},{"id":596133,"name":"Wei‐Kung Wang","orcid":"0000-0002-6670-4663","position":8,"is_corresponding":false},{"id":968307,"name":"Yu-Ching Dai","orcid":"0009-0008-4855-0374","position":0,"is_corresponding":true}],"reference_count":78,"raw_metadata":null,"created_at":"2026-07-19T01:16:19.336238Z","pmid":"37428104","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}